---
title: "CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million"
url: "https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-20"
section: "Financings"
tickers: "NASDAQ:CNSP"
source: "https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm"
summary: "The company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025."
---

By the aibio.space news desk.

Sources

- [CNS Pharmaceuticals, Inc. 8-K (2025-03-20)](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm)
- [CNS Pharmaceuticals, Inc. 424B5 (2025-03-20)](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001755/cns_424b5.htm)

[CNSP](https://aibio.space/companies/cns-pharmaceuticals/)

2025-03-20

# CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million

Tickers [CNSP](https://aibio.space/companies/cns-pharmaceuticals/)

The company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.

## Key facts

- **Company**: CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

- **News type**: Financings

- **Primary source**: [CNS Pharmaceuticals, Inc. 8-K (2025-03-20)](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm)

*Glass office towers seen from below. CC0, via rawpixel. The picture shows the field, not the companies named.*

CNS Pharmaceuticals, Inc. (Nasdaq: [CNSP](https://aibio.space/companies/cns-pharmaceuticals/)) increased the amount of stock it can sell under its sales agreement with A.G.P./Alliance Global Partners to $43.5 million.

The agreement, signed on July 26, 2024, is an at-the-market program, which lets a company sell new shares into the market from time to time at current prices. It started at up to $5.2 million. The company raised the cap to $30.2 million on July 30, 2024. On March 20, 2025, it raised it again to $43.5 million, which includes $6,447,229.14 left over from the earlier $30.2 million, according to its [filing](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm).

As of March 20, 2025, CNS had sold 2,522,755 shares under the program for gross proceeds of approximately $23.75 million. It had 2,944,381 shares of common stock outstanding on that date.

The sales are made under the company's shelf registration statement on Form S-3, which became effective on May 17, 2024. The $43.5 million is part of the $75,000,000 of securities the company may sell under that registration.

The last sale price of CNS stock on March 19, 2025 was $3.81 per share, the [prospectus supplement](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001755/cns_424b5.htm) shows.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CNSP

CNS Pharmaceuticals, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million", 2025-03-20, https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/